drugset / Trial / NCT04587479
A First-in-Human Study of JAB-8263 in Adult Patients With Advanced Solid Tumors
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 1, first-in-human, open-label study of JAB-8263 to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT. 30 subjects with advanced solid tumor will be enrolled.
Timeline
- Start
- 2020-11-23
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JAB-8263 | Small molecule | — | Oral |
Indications
No indication recorded.